Evaluation of 70-150-μm doxorubicin-eluting beads for transcatheter arterial chemoembolization in the rabbit liver VX2 tumour model.
Evaluation of 70-150-μm doxorubicin-eluting beads for transcatheter arterial chemoembolization in the rabbit liver VX2 tumour model.
复制标题
DOI:
10.1007/s00330-015-4197-y
复制
发表时间:
2016-10
影响因子:
5.9
通讯作者:
Liapi EA
中科院分区:
文献类型:
--
作者:
Gholamrezanezhad A;Mirpour S;Geschwind JF;Rao P;Loffroy R;Pellerin O;Liapi EA
To evaluate the pharmacokinetic profile (PK) and embolization effect of 70–150µm doxorubicin eluting beads (DEB) following intra-arterial injection (i.a.) in the rabbit liver VX2 tumour model. In this ACUC approved study, 25 white New Zealand rabbits were randomly assigned into small DEB Group (SDB, n=7, 70–150µm DEB), large DEB Group (LDB, n=7, 100–00µm DEB), untreated controls (n=7), and doxorubicin controls (n=4, without tumour, received i.a. 12.5 mg doxorubicin). Plasma PK was assessed up to 180 min post-injection. Drug tissue and liver enzyme levels, radiologic tumor response and histopathologic tumour necrosis were assessed at 7 days. Mean tumour doxorubicin concentrations were 922.83nM (SD=722.05) and 361.48nM (SD= 473.23) for the SDB and LDB, respectively (p= 0.005). There was no statistically significant difference in tumour doxorubicinol, plasma doxorubicin and doxorubicinol PK values. More beads were observed in the SDB tumours (p=0.01). Liver enzymes increased and gradually declined over the observation period, with significantly higher values in the SDB. In this preclinical study, plasma PK of i.a. injected 70–150µm DEB was not different than that of 100–300µm DEB. More beads and higher tissue doxorubicin levels were observed in the SDB tumours.